Pliant Therapeutics, Inc.
PLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $1,580 | $9,685 | $7,572 |
| % Growth | -100% | -83.7% | 27.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1,580 | $9,685 | $7,572 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $169,310 | $127,797 | $96,936 | $77,549 |
| G&A Expenses | $59,055 | $57,928 | $39,949 | $27,558 |
| SG&A Expenses | $59,055 | $57,928 | $39,949 | $27,558 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $228,365 | $185,725 | $136,885 | $105,107 |
| Operating Income | -$228,365 | -$184,145 | -$127,200 | -$97,535 |
| % Margin | – | -11,654.7% | -1,313.4% | -1,288.1% |
| Other Income/Exp. Net | $18,061 | $22,809 | $3,879 | $272 |
| Pre-Tax Income | -$210,304 | -$161,336 | -$123,321 | -$97,263 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$210,304 | -$161,336 | -$123,321 | -$97,263 |
| % Margin | – | -10,211.1% | -1,273.3% | -1,284.5% |
| EPS | -3.47 | -2.75 | -2.94 | -2.71 |
| % Growth | -26.2% | 6.5% | -8.5% | – |
| EPS Diluted | -3.47 | -2.75 | -2.94 | -2.71 |
| Weighted Avg Shares Out | 60,539 | 58,719 | 42,016 | 35,846 |
| Weighted Avg Shares Out Dil | 60,539 | 58,719 | 42,016 | 35,846 |
| Supplemental Information | – | – | – | – |
| Interest Income | $21,085 | $24,076 | $4,670 | $272 |
| Interest Expense | $3,024 | $1,267 | $791 | $0 |
| Depreciation & Amortization | $2,125 | $1,841 | $3,681 | $1,535 |
| EBITDA | -$205,155 | -$158,228 | -$118,849 | -$95,728 |
| % Margin | – | -10,014.4% | -1,227.1% | -1,264.2% |